BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8103761)

  • 1. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro.
    Hill BT; van der Graaf WT; Hosking LK; de Vries EG; Mulder NH; Whelan RD
    Int J Cancer; 1993 Sep; 55(2):330-7. PubMed ID: 8103761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.
    Hill BT; Hosking LK
    Cancer Chemother Pharmacol; 1994; 33(4):317-24. PubMed ID: 8281626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies.
    Merlin JL; Guerci A; Marchal S; Missoum N; Ramacci C; Humbert JC; Tsuruo T; Guerci O
    Blood; 1994 Jul; 84(1):262-9. PubMed ID: 7912556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro characterization of S9788, a new modulator of multidrug resistance].
    Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
    Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
    Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
    Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
    Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of verapamil and S9788 on MDR-1 mRNA expression studied by in situ hybridization.
    Joly P; Lallemand A; Oum'Hamed Z; Trentesaux C; Idoine O; Desplaces A
    Anticancer Res; 1996; 16(6B):3609-14. PubMed ID: 9042229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
    Pérez V; Pierré A; Léonce S; Anstett M; Atassi G
    Anticancer Res; 1993; 13(4):985-90. PubMed ID: 8352569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line.
    Massart C; Gibassier J; Raoul M; Pourquier P; Leclech G; Robert J; Lucas C
    Anticancer Drugs; 1995 Feb; 6(1):135-46. PubMed ID: 7756676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.
    Julia AM; Roché H; Berlion M; Lucas C; Milano G; Robert J; Bizzari JP; Canal P
    Br J Cancer; 1994 May; 69(5):868-74. PubMed ID: 8180016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788.
    Demmer A; Dunn T; Hoof T; Kubesch P; Tümmler B
    Eur J Pharmacol; 1996 Nov; 315(3):339-43. PubMed ID: 8982674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
    Sebille S; Morjani H; Poullain MG; Manfait M
    Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
    Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
    Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
    Belhoussine R; Morjani H; Manfait M
    Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.
    Merlin JL; Marchal S; Ramacci C; Dieterlen A; Schultz G; Lucas C; Poullain MG; Berlion M
    Cytometry; 1995 Aug; 20(4):315-23. PubMed ID: 7587719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Quantitative cytological study of the activity of a new resistance modulator, S 9788, on human leukemic cells using multiparametric image analysis].
    Oum'Hamed Z; Berlion M; Millot-Broglio C; Dufer J; Joly P; Bizzari JP; Desplaces A
    Bull Cancer; 1994 Mar; 81(3):203-11. PubMed ID: 7894128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft.
    Massart C; Gibassier J; Raoul M; Denais A; Maugendre S; Darcel F; Lucas C
    Anticancer Drugs; 1996 May; 7(3):321-30. PubMed ID: 8792007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide.
    Hosking LK; Whelan RD; Shellard SA; Davies SL; Hickson ID; Danks MK; Hill BT
    Int J Cancer; 1994 Apr; 57(2):259-67. PubMed ID: 7908897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.
    Mickisch GH; Roehrich K; Koessig J; Forster S; Tschada RK; Alken PM
    J Urol; 1990 Sep; 144(3):755-9. PubMed ID: 1974934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.